PMC9099359_01
PMC9099359_02
The changes of Th1 and Th2 cells after 8 weeks treatment of Dupilumab. The proportion of IL-4+Th2 cells increased from 4.55% to 20.20%, IL-13+Th2 cells increased from 32.32% to 49.84% after treatment in patient #2.
fmed-09-813313-g0001.jpg
PMC9099359_02_fmed-09-813313-g0001.jpg
F1
Interestingly, the proportion of IL-4 and IL-13 producing Th2 cells were increased after Dupilumab treatment (Figure 1, Table 2).